NEMUS Bioscience Announces NB2222 Pain and Anti-Addiction Data Accepted for Presentation at Upcoming Society of Neuroscience Meeting
COSTA MESA, CA -- (Marketwired) -- 07/17/17 -- NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that data recently obtained from the company's research and development partner, the University of Mississippi (UM), was accepted for presentation at the 2017 Annual Meeting of the Society of Neuroscience held in Washington, D.C. on November 11th-15th. The data being presented will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator. Additional data will also be presented detailing the anti-addictive potential of NB2222 in an animal model of opioid addiction. The in vivo research was led by Professor Kenneth Sufka of the University of Mississippi based on the molecular cannabinoid discovery work performed by the team at ElSohly Laboratories, Inc. (ELI) in collaboration with the University, spearheaded by Dr. Mahmoud ElSohly, who also holds a faculty appointment at the University.
"NEMUS has previously reported that our proprietary analogue of CBD, NB2222, has exhibited a competitive bioavailability profile when compared to plant-derived CBD, penetrating the blood-brain barrier to enter the central nervous system, as well as all major organs, especially the liver, in animal studies conducted to-date," commented Brian Murphy, MD, MBA, the NEMUS CEO and Chief Medical Officer. "The data being presented by Dr. Sufka is a pivotal start to developing the analogue of CBD to potentially address medical indications in multiple organ systems, especially the eye, brain and diseases of the liver."
Dr. Kenneth Sufka, professor of Psychology and Pharmacology and Research Professor with the National Center for Natural Products Research at UM stated, "We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall."
"The discovery team is very pleased with the performance of this analogue of CBD in the studies that have been performed so far," reported Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research at the University of Mississippi School of Pharmacy and co-inventor of the CBD analogue. "We believe that bio-engineered cannabinoids offer a unique opportunity to potentially enhance the efficacy and safety profile of this class of therapeutics. We look forward to working with NEMUS in advancing other cannabinoid-based therapies across a spectrum of diseases."
Dr. Murphy noted, "It appears that NB2222 could have a number of uses beyond pain management and ocular conditions, and moving forward, Nemus will consider strategic collaborations for this CBD analogue."
FORWARD LOOKING STATEMENTS
Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties, including statements about the potential benefits of NB2222 and the timing of our near term, intermediate term and long term goals. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.
ABOUT NEMUS BIOSCIENCE, INC.
The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS' strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.
For more information, visit http://www.nemusbioscience.com.
NEMUS Investor Relations
PCG Advisory Group
NEMUS Media Relations
JV Public Relations
Source: NEMUS Bioscience, Inc.
Released July 17, 2017